A phase 1/2 trial investigating REGN5668, a MUC16×CD28 costimulatory bispecific antibody, in combination with other targeted therapies in patients with recurrent ovarian or endometrial cancer: trial in progress update

International Journal of Gynecological Cancer 2026

View at publisher
Authors: Roisin Eilish O'Cearbhaill, Sara Bouberhan, Els Van Nieuwenhuysen, Ira Seth Winer, John L. Hays, John William Moroney, Dario R. Roque, Mihae Song, Victor Moreno, Lainie P. Martin, Jill Tseng, M.P. Barretina Ginesta
+8 more Luisa Sánchez, Suk‐Young Yoo, Tahmineh Tabrizian, Mary Jane Peterman, Israel Lowy, Thomas S. Uldrick, Gloria Shining Huang, Elizabeth C. Miller
DOI: 10.1016/j.ijgc.2025.104394
Cited by: 0

Fields of Study & Subjects

Ovarian cancer diagnosis and treatment Cancer Immunotherapy and Biomarkers Monoclonal and Polyclonal Antibodies Research

Publication details

Journal / source
International Journal of Gynecological Cancer
Volume
36
Issue
2
Pages
104394–104394
Publication date
1 February 2026
Language
EN